Skip to main content
Article thumbnail
Location of Repository

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

By A. Smith Lesley, Victoria Cornelius, Christopher J. Plummer, Gill Levitt, Mark Verrill, Peter Canney and Alison Jones

Abstract

Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.<br/><br/>Methods: Randomized controlled trials were sought using comprehensive searches of electronic databases in June 2008. Reference lists of retrieved articles were also scanned for additional articles. Outcomes investigated were early or late clinical and sub-clinical cardiotoxicity. Trial quality was assessed, and data were pooled through meta-analysis where appropriate.<br/><br/>Results: Fifty-five published RCTs were included; the majority were on women with advanced breast cancer. A significantly greater risk of clinical cardiotoxicity was found with anthracycline compared with non-anthracycline regimens (OR 5.43 95% confidence interval: 2.34, 12.62), anthracycline versus mitoxantrone (OR 2.88 95% confidence interval: 1.29, 6.44), and bolus versus continuous anthracycline infusions (OR 4.13 95% confidence interval: 1.75, 9.72). Risk of clinical cardiotoxicity was significantly lower with epirubicin versus doxorubicin (OR 0.39 95% confidence interval: 0.20, 0.78), liposomal versus non-liposomal doxorubicin (OR 0.18 95% confidence interval: 0.08, 0.38) and with a concomitant cardioprotective agent (OR 0.21 95% confidence interval: 0.13, 0.33). No statistical heterogeneity was found for these pooled analyses. <br/><br/>A similar pattern of results were found for subclinical cardiotoxicity; with risk significantly greater with anthracycline containing regimens and bolus administration; and significantly lower risk with epirubicin, liposomal doxorubicin versus doxorubicin but not epirubicin, and with concomitant use of a cardioprotective agent. Low to moderate statistical heterogeneity was found for two of the five pooled analyses, perhaps due to the different criteria used for reduction in Left Ventricular Ejection Fraction. Meta-analyses of any cardiotoxicity (clinical and subclinical) showed moderate to high statistical heterogeneity for four of five pooled analyses; criteria for any cardiotoxic event differed between studies. Nonetheless the pattern of results was similar to those for clinical or subclinical cardiotoxicity described above.<br/><br/>Conclusions: Evidence is not sufficiently robust to support clear evidence-based recommendations on different anthracycline treatment regimens, or for routine use of cardiac protective agents or liposomal formulations. There is a need to improve cardiac monitoring in oncology trials.<br/

Topics: RM, RC0254
Year: 2010
OAI identifier: oai:eprints.soton.ac.uk:161955
Provided by: e-Prints Soton

Suggested articles

Citations

  1. (1995). A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. doi
  2. (2003). Altman DG: Measuring inconsistency in meta-analyses. BMJ
  3. (2009). Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. doi
  4. (1999). Alvarez E: Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. doi
  5. (1991). Anversa P: Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res doi
  6. (1991). BG: Comparative effectiveness of two combined modality regimens in the treatment of surgical stage III Hodgkin's disease in children. An 8-year follow-up study by the Pediatric Oncology Group. doi
  7. (1987). Buceta JE: Prevention of adriamycininduced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv doi
  8. (2008). cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. doi
  9. (2008). Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. doi
  10. (1991). Chapman PJ: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
  11. (1998). CL: Randomized prospective clinical trial of highdose epirubicin and dexrazoxane in patients with advanced breast Smith et al.
  12. (2007). Clegg A: Clinical and costeffectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: A systematic review. doi
  13. (1985). CW: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
  14. (1997). Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin.
  15. (2007). Dargie HJE: Drug-induced cardiovascular disorders. Drug Safety doi
  16. (2006). Dexrazoxane Study G: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/ metastatic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology doi
  17. (1994). Diaz-Maqueo JC: Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD). Medical & Pediatric Oncology doi
  18. (2007). DJ: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. doi
  19. (2005). DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
  20. (2006). Ergin AE: Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. doi
  21. (2009). EUROCARE Working Group: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. doi
  22. (2004). Ewer MS: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation
  23. (1987). Feuilhade F: Randomized trial comparing mitoxantrone with adriamycin in advanced breast cancer. Presse Medicale doi
  24. (2005). G: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicininduced cardiotoxicity. Circulation
  25. (1997). Gams R: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
  26. (1996). GJ: Comparison of mitozantrone and epirubicin in advanced breast cancer. Clinical Oncology doi
  27. (2001). Glimelius B: A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncologica doi
  28. (1988). Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin.
  29. (2004). Groupmedline CBCS: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology
  30. (2002). Groupmedline TDS: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer doi
  31. (1996). Horowitz ME: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
  32. (1988). I: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
  33. (1995). Iannitto E, Perrotti A: Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma doi
  34. (1978). JR: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep
  35. (1993). K: A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clinical Oncology doi
  36. (2006). Karlic H: Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. doi
  37. (1991). Lansimies E: Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. doi
  38. (2008). LCME: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews doi
  39. (2010). LCME: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database of Systematic Reviews doi
  40. (2009). LCME: Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews doi
  41. (2009). Leisenring WM: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ doi
  42. (1988). LG: Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer. doi
  43. (1991). LH: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. doi
  44. (2005). Lippman SM: Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. doi
  45. (2005). LJ: Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs doi
  46. (2007). Localio A: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med doi
  47. (1992). Lovelace JV: Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial. doi
  48. (2004). LW: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of Oncology doi
  49. (2001). LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.[see comment].
  50. (1992). M: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.[erratum appears in J Clin Oncol doi
  51. (1992). Magnasco H: Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP.[see comment]. Annals of Oncology
  52. (1995). Manfreda D: Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. doi
  53. (2007). Medina-Sanson A: Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatric Hematology & Oncology doi
  54. (1991). MF: A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer doi
  55. (2008). MM: Caring for adult survivors of childhood cancer. Curr Treat Options Oncol doi
  56. (1986). N: Meta-analysis in clinical trials. Control Clin Trials doi
  57. (2000). Nahata MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf doi
  58. (1986). NM: A trial of chemotherapy in patients with osteosarcoma. (A report to the Medical Research Council by the working party on bone sarcoma.
  59. (2004). O: Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.
  60. (1998). Oosterom AT: Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. doi
  61. (1986). Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treatment Reports doi
  62. (1990). Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Seminars in Oncology
  63. (1988). Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. doi
  64. (1993). Prognostic subgroups: The key factor for treatment outcome in metastatic breast cancer. Results of three-arm randomized multicenter trial comparing doxorubicin, epirubicin and mitoxantrone each in combination with cyclophosphamide. Onkologie doi
  65. (1989). Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. doi
  66. (1990). Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer doi
  67. (1991). Ribecco A: Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. Cancer Investigation doi
  68. (1996). Rm: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
  69. (1989). RS: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. doi
  70. (1983). S: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol
  71. (2007). SH: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. doi
  72. (2001). Siegel SE: Comparison of long-term outcome of children and adolescents with disseminated nonlymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Medical & Pediatric Oncology doi
  73. (1998). Silingardi V: Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica doi
  74. (2008). Soefje SAE: A review of the cardiovascular effects of oncology agents. doi
  75. (2001). Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ doi
  76. (1986). Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide. Medical & Pediatric Oncology doi
  77. (2002). Tura S: Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: Final analysis of a randomized clinical study. Haematologica
  78. (2001). Viaro D: Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
  79. (2005). von Minckwitz G: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Annals of Oncology doi
  80. (2002). Voute PA: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review (Structured abstract). Annals of Oncology doi
  81. (1991). Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.